Antagomir to prevent cardiac arrhythmia (2019-069)
IP Status: Provisional Patent Application Filed
- Therapeutic (alone or in combination) for cardiac arrhythmias
- Research tool to knock-down miR-448 and or upregulate SCN5A
- Cancer therapeutic (for cancers where miR-448 is relevant)
Arrhythmic cardiomyopathy can cause severe problems including cardiac arrest and death. Unfortunately, many of the therapeutics to treat arrhythmias can actually have pro-arrhythmic side effects. This technology is an antagomir targeting miR-448 (anti-miR-448), a microRNA linked to the downregulation of the sodium channel SCN5A. Relieving the inhibition of miR-448 facilitates the upregulation of SCN5A, which is protective against arrhythmia, while bypassing the potential pro-arhythmic side-effects of existing therapies.
Phase of Development
In vitro and in vivo testing.
This technology is now available for:
- Sponsored research
Researchers: Sam Dudley, MD, PhD , Professor of Medicine, Cardiovascular Division, Medical School
swap_vertical_circlecloud_downloadSupporting documents (0)Additional files may be available once you've completed the transaction for this product. If you've already done so, please log into your account and visit My account / Downloads section to view them.